What is it about?
To evaluate the efficacy and safety of most selective serotonin reuptake inhibitor drug, escitalopram, in delaying ejaculation in patients with premature ejaculation (PE).
Featured Image
Photo by Kristina Litvjak on Unsplash
Why is it important?
Premature ejaculation is the most common form of sexual dysfunction in men, affecting up to 21% of men aged 18 to 59 years in the United States.1 In general, however, the prevalence of PE is reported as being between 22% and 38% of adult male population
Perspectives
It seems that escitalopram provides a clear advantage in improving geometric mean IELT compared with other SSRIs. Clearly, the issue of placebo-controlled trials will remain the ultimate litmus test of treatment efficacy. Nearly all of the current pharmacotherapy for PE are palliative and do not Btreat[ or Bcure[ the problem actually. Although the therapeutic effect of a drug is seen within weeks, in minimum, alleviation of problem for a much longer time is required.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation, Journal of Clinical Psychopharmacology, October 2007, Wolters Kluwer Health,
DOI: 10.1097/jcp.0b013e31814b98d4.
You can read the full text:
Resources
Contributors
The following have contributed to this page
